Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Innovent's Partner Ollin Biosciences

Innovent's Partner Ollin Biosciences

Series BUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$330Msum of rounds with a disclosed amount only
Named investors
7
Financing history
1 rounds
  1. Jun 24, 2026
    Series B · $330M (disclosed)
    Arch Venture Partners (lead)Commodore Capital (participant)Canada Pension Plan Investment Board (participant)RA Capital Management, LP (participant)Monograph Capital Advisors (uk), LLP (participant)TCGX (lead)Blackstone Multi-Asset Investing (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies C”
Investors on record
7 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Jun 24, 2026
    Innovent's Partner Ollin Biosciences announced Series B of $330,000,000, led by TCGX, ARCH Venture Partners
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company